4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl acetate

AZD3759 is a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) on the basis of gefitinib and has been proven to enter the central nervous system. Although the promising antitumor effects of AZD3759 on non-small cell lung cancer (NSCLC) have been demonstrated in clinical trials, the regulatory effects of this inhibitor on the antitumor efficacy of radiation (RA) are unclear. AZD3759 Intermediate 2 is a key intermediate in the synthesis of AZD3759.

AZD3759 Intermediate 2 can be used as a pharmaceutical intermediate.